For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.

Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Scientists uncover how Ffar4 regulates sugar cravings through gut microbiota, revealing pantothenate as a key mediator to ...

The rise of GLP-1 drugs is sending the Diageo share price lower. But Stephen Wright thinks investors should try to avoid ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

The series tackles the ‘GLP-1 revolution,’ created to educate consumers about the medication’s potential uses and side ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it ...